The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2023 | The impact of novel targeted & immune therapies in leukemia
Norbert-Claude Gorin, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, comments on the advent of novel targeted and immune therapies in the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (AML), highlighting their impact on stem cell transplantation (SCT). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
